Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.54 |
| ▸ | CTRC | Q99895 | 4/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3642416 | 0.96 | F2 (0.55) | F2PRSS2CTRCF10 | |
| SCHEMBL3645053 | 0.94 | F2 (0.54) | F2PRSS2CTRCF10 | |
| SCHEMBL8100186 | 0.89 | F2 (0.59) | F2PRSS2CTRCF10 | |
| SCHEMBL3647138 | 0.88 | F2 (0.71) | F2PRSS2CTRCF10 | |
| SCHEMBL3642918 | 0.84 | F2 (0.70) | F2PRSS2CTRCF10 | |
| SCHEMBL3642375 | 0.82 | F2 (0.55) | F2PRSS2CTRC | |
| SCHEMBL3637680 | 0.81 | F2 (0.69) | F2PRSS2CTRCF10 | |
| SCHEMBL8095369 | 0.81 | F2 (0.52) | F2PRSS2CTRCF10 | |
| SCHEMBL12920117 | 0.80 | F2 (0.61) | F2PRSS2CTRCF10 | |
| Iodide SCHEMBL976494 | 0.80 | F2 (0.51) | F2PRSS2CTRCF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426433-B2 | Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution | Obschestvo S Ogranichennoi Otvetsttvennoctiyu “Bionika” (RU) | 2013-04-23 | — | — | US | disclosed |
| US-8426433-B2 | Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution | Obschestvo S Ogranichennoi Otvetsttvennoctiyu “Bionika” (RU) | 2013-04-23 | — | — | US | disclosed |
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | Obschestvo S Organichennoi Otvetsttvennoctiyu "Bio (RU) | 2011-01-06 | — | — | US | disclosed |
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | Obschestvo S Organichennoi Otvetsttvennoctiyu "Bio (RU) | 2011-01-06 | — | — | US | disclosed |
| EP-2178838-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | Obschestvo S Ogranichennoi Otvetsttvennoctiyu "Bionika" (RU) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009002228-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | F2, PROC, PLG | F2 1/4885PRSS2 447/4885CTRC 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.